Hematological Oncology : Impact Factor & More
eISSN: 1099-1069pISSN: 0278-0232
Share this on:
Key Metrics
CiteScore 
5.3
Eigenfactor
0.001 - 0.005
Impact Factor
< 5
SJR
Q3Oncology
SNIP
1.04
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Hematological Oncology
Hematological Oncology Journal Specifications
| Overview | |
| Publisher | WILEY |
| Language | English |
| Frequency | Quarterly |
| General Details | |
| Language | English |
| Frequency | Quarterly |
| Publication Start Year | 1983 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Hematological Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Hematological Oncology
Title not available
- 1 May 2026
- Hematological Oncology
Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real-Life Multicenter Experience. Results From the REDOT_MCL Study.
- 1 May 2026
- Hematological oncology
TRIM37-Mediated Ubiquitination and Degradation of KMT2D Activates JAK2-STAT3 Signaling to Promote Diffuse Large B-Cell Lymphoma Progression.
- 20 Apr 2026
- Hematological oncology
The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non-Secretory Relapse-A Retrospective Cohort Study.
- 7 Apr 2026
- Hematological oncology
Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor‐Naïve Patients With Myelofibrosis From the Multicenter, Open‐Label, Phase 2 Study (REFINE)
- 1 Mar 2026
- Hematological Oncology
Anatomical Localization-Based Analysis of Relapsed Secondary Central Nervous System Aggressive B-Cell Lymphoma (R-SCNSL).
- 1 Mar 2026
- Hematological oncology
Title not available
- 1 May 2026
- Hematological Oncology
Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real-Life Multicenter Experience. Results From the REDOT_MCL Study.
- 1 May 2026
- Hematological oncology
TRIM37-Mediated Ubiquitination and Degradation of KMT2D Activates JAK2-STAT3 Signaling to Promote Diffuse Large B-Cell Lymphoma Progression.
- 20 Apr 2026
- Hematological oncology
The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non-Secretory Relapse-A Retrospective Cohort Study.
- 7 Apr 2026
- Hematological oncology
Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor‐Naïve Patients With Myelofibrosis From the Multicenter, Open‐Label, Phase 2 Study (REFINE)
- 1 Mar 2026
- Hematological Oncology
Anatomical Localization-Based Analysis of Relapsed Secondary Central Nervous System Aggressive B-Cell Lymphoma (R-SCNSL).
- 1 Mar 2026
- Hematological oncology
FAQs on Hematological Oncology
How long has Hematological Oncology been actively publishing? 
What is the publishing frequency of Hematological Oncology?
How many articles did Hematological Oncology publish last year?
What is the eISSN & pISSN for Hematological Oncology?
What is Citescore for Hematological Oncology?
What is SNIP score for Hematological Oncology?
What is the SJR for Hematological Oncology?
Who is the publisher of Hematological Oncology?
